Formulation Matters: Nutrient Availability and Label Accuracy of Supplements for Age-Related Macular Degeneration
Investigative Ophthalmology & Visual Science · 2026-11-17 · 67 (13) · 32
DOI: 10.1167/iovs.67.13.32 ↗At a glance
Randomisierte kontrollierte Studie in Investigative Ophthalmology & Visual Science, published on 2026-11-17. Written by Alexandra Sheila P M de Koning-Backus and 4 co-authors. Institution: Department of Ophthalmology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. Major MEDLINE topics: Macular Degeneration, Dietary Supplements, Zeaxanthins, Lutein. 85 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
AREDS2-based supplements can reduce progression to advanced AMD, but commercially available supplements can differ in characteristics. The aim of this study was to compare two AMD supplements with different coatings for their effects on serum lutein and zeaxanthin (L&Z) levels, and to analyze commercially available supplements for label accuracy and levels of AREDS2-relevant nutrients.
Methods
In a randomized, open-label trial, 11 healthy adults aged 25 to 64 years received either AREDS2 formulation delivered in a softgel (B1) or a L&Z-containing herbal-coated tablet (B2) for four weeks, followed by crossover to the alternate intervention. Serum L&Z levels were measured at baseline and after each intervention. Twenty-three commercially available AMD supplements were analyzed for their content of L&Z, vitamins C and E, zinc, copper, and omega-3 fatty acids. Measured values were compared with product label claims and AREDS2 reference standards.
Results
B1 significantly increased serum levels of lutein (0.13 → 0.31 µmol/L, P = 0.003) and zeaxanthin (0.08 → 0.11 µmol/L, P = 0.003), whereas B2 produced no measurable change. Commercial supplement analysis revealed substantial variability: lutein ranged from 76%-207% and zeaxanthin from 59%-326% of declared amounts. Only four of 23 products matched AREDS2 formulation; several were overfortified, and some lacked detectable nutrient levels.
Conclusions
This study demonstrates that dosage form significantly influences nutrient-availability after intake of AMD-supplements, and that commercial products frequently deviate from their labeled nutrient content. These findings are relevant for AMD management and underscore the need for standardized testing and stricter quality control.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Public Health and Primary Care/Health Campus The Hague, Leiden University Medical Center, The Hague, The Netherlands.
- University Eye Clinic Maastricht, Maastricht, The Netherlands.
- Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Institute of Molecular and Clinical Ophthalmology, University of Basel, Basel, Switzerland.
Cite
APA
de Koning-Backus, A. S. P. M., Kiefte-de Jong, J. C., Berendschot, T. J. M., Smoor, M. A., & Klaver, C. C. W. (2026). Formulation Matters: Nutrient Availability and Label Accuracy of Supplements for Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science, 67(13), 32. https://doi.org/10.1167/iovs.67.13.32
Vancouver
de Koning-Backus ASPM, Kiefte-de Jong JC, Berendschot TJM, Smoor MA, Klaver CCW. Formulation Matters: Nutrient Availability and Label Accuracy of Supplements for Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 2026;67(13):32. doi:10.1167/iovs.67.13.32
BibTeX
@article{deKoningBackus2026,
author = {de Koning-Backus, Alexandra Sheila P M and Kiefte-de Jong, Jessica C and Berendschot, Tos J M and Smoor, Magda A and Klaver, Caroline C W},
title = {Formulation Matters: Nutrient Availability and Label Accuracy of Supplements for Age-Related Macular Degeneration},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
volume = {67},
number = {13},
pages = {32},
doi = {10.1167/iovs.67.13.32}
}
EUVIMED